Centessa Pharmaceuticals plc / Fundamentals
Income statement
- Net revenue
€12.84M - Cost of goods sold
€577.33K - Gross profit
€12.51M - SG&A expenses
€43.41M - R&D expenses
€156.67M - EBITDA
-€183.06M - D&A
€778.43K - EBIT
-€176.71M - Interest expenses
€9.24M - EBT
-€194.31M - Tax expenses
€3.28M - Net income
-€197.22M
Cash flow statement
- Net deferred tax
€3.14M - Non-cash items
€29.07M - Changes in working capital
€47.56M - Operating cash flow
-€123.18M - Capex
€136.98K - Other investing cash flow
-€125.20M - Net investing cash flow
-€164.69M - Total cash dividends paid
€0.00 - Issuance of common stock
€209.26M - Debt repayment
€0.00 - Other financing cash flow
€7.88M - Net financing cash flow
€217.14M - Foreign exchange effects
-€429.76K - Net change in cash
-€71.17M - Cash at end of period
€37.88M - Free cash flow
-€123.04M
Balance sheet
- Cash and cash equivalents
€37.88M - Cash and short-term investments
€214.64M - Total receivables
€37.75M - Inventory
€0.00 - Other current assets
€4.75M - Total current assets
€257.14M - Property, plant & equipment
€9.65M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€131.33M - Other non-current assets
€1.47M - Total non-current assets
€164.17M - Total assets
€421.31M - Accounts payable
€4.87M - Short-term debt
€1.12M - Other current liabilities
€19.20M - Total current liabilities
€25.42M - Long-term debt
€100.58M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€24.83K - Total non-current liabilities
€100.60M - Total liabilities
€126.02M - Common stock
€310.76K - Retained earnings
-€911.89M - Other equity
€1.36M - Total equity
€295.28M - Total liabilities and shareholders' equity
€421.31M
Company information
- Market capitalization
€1.50B - Employees
77 - Enterprise Value
€1.57B
Company ratios
- Gross margin
-
97.4% Much better than peer group: -106,485,552,164,402.1% - EBITDA margin
-
-1,425.6% Much better than peer group: -585,528,931,761,946.0% - EBIT margin
-
-1,376.1% Much better than peer group: -590,995,085,732,025.9% - EBT margin
-
-1,513.1% Much better than peer group: -590,293,765,025,945.1% - Net margin
-
-1,535.8% Much better than peer group: -590,293,765,026,958.4% - ROE
-
-66.8% Much worse than peer group: -11.2% - ROA
-
-46.8% Worse than peer group: -34.4% - Asset turnover
-
3.0% Even with peer group: 6.1% - FCF margin
-
-960.3% Much better than peer group: -491,843,921,460,417.1% - FCF yield
-8.2% - Efficiency ratio
1,525.6% - Net sales per employee
-
€166.77K - Net income per employee
-
-€2.56M